We’re loaded up with news items this week!
First, the good news:
Takeda shows healthy financial results, mainly due to Actos sales.
Certain ACE inhibitors potentially useful in stalling dementia?
Can diabetes drugs improve the effectiveness of cancer therapy with platinum agents? It just may be so!
Schwarz Pharma’s Parkinson’s patch approved.
But, it’s been a rough week for some companies:
Medicis hit for off-label marketing in a whistleblower case
J&J being probed on multiple fronts
Purdue gets hit once, then again, in court for sales/marketing practices with Oxycontin.
Device makers bribing doctors?
Questions being raised about reimbursements for anemia drugs.
Drug-infused stents being widely used off-label.
And, in a matter that has a lot of long-term implications, Brazil contributing to the growing tide of companies who practice “patent thievery” with drug treatments.
Leave a Reply